Skip to main content
NIH funding notice PAR-13-267

Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01)

Closed on January 7, 2016.

Posted
July 8, 2013
Close date
January 7, 2016
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,172,566 in first-year total cost, median $1,086,283.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-M (03)]1
  2. Special Emphasis Panel[ZMH1 ERB-M (05)]1

Most frequent institutions

  1. JOHNS HOPKINS UNIVERSITY1
  2. TEMPLE UNIV OF THE COMMONWEALTH1
Competing awards under PAR-13-267 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2015'Intranasal Insulin Therapy for HIV- Associated Neurocognitive Disorders'1P01MH105280-01A1HAUGHEY, NORMAN JMCARTHUR, JUSTIN CHARLES.JOHNS HOPKINS UNIVERSITY, MD$1,062,066ZMH1
2014NeuroAIDS Therapeutics-Targeting Immune Polarization of Macrophages in CNS1P01MH105303-01DOUGLAS, STEVEN DANIELRAPPAPORT, JAYTEMPLE UNIV OF THE COMMONWEALTH, PA$1,110,500ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-13-267: Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01) | ScienceDex | ConductScience